Literature DB >> 33731362

Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase.

Hongzhuang Peng1, Joel Cassel2, Daniel S McCracken2,3, Jeremy W Prokop4,5, Eleonora Sementino6, Mitchell Cheung6, Paul R Collop7, Alexander Polo2, Surbhi Joshi2, Jacob P Mandell2, Kasirajan Ayyanathan2, David Hinds4,5, S Bruce Malkowicz8, J William Harbour9, Anne M Bowcock10, Joseph Salvino2, Eileen J Kennedy7, Joseph R Testa11, Frank J Rauscher2.   

Abstract

BAP1 is an ubiquitin hydrolase whose deubiquitinase activity is mediated by polycomb group-like protein ASXL2. Cancer-related BAP1 mutations/deletions lead to loss-of-function by targeting the catalytic ubiquitin C-terminal hydrolase (UCH) or UCH37-like domain (ULD) domains of BAP1, and the latter disrupts binding to ASXL2, an obligate partner for BAP1 enzymatic activity. However, the biochemical and biophysical properties of domains involved in forming the enzymatically active complex are unknown. Here, we report the molecular dynamics, kinetics, and stoichiometry of these interactions. We demonstrate that interactions between BAP1 and ASXL2 are direct, specific, and stable to biochemical and biophysical manipulations as detected by isothermal titration calorimetry (ITC), GST association, and optical biosensor assays. Association of the ASXL2-AB box greatly stimulates BAP1 activity. A stable ternary complex is formed, comprised of the BAP1-UCH, BAP1-ULD, and ASXL2-AB domains. Stoichiometric analysis revealed that one molecule of the ULD domain directly interacts with one molecule of the AB box. Real-time kinetic analysis of the ULD/AB protein complex to the BAP1-UCH domain, based on surface plasmon resonance, indicated that formation of the ULD/AB complex with the UCH domain is a single-step event with fast association and slow dissociation rates. In vitro experiments validated in cells that the ASXL-AB box directly regulates BAP1 activity. IMPLICATIONS: Collectively, these data elucidate molecular interactions between specific protein domains regulating BAP1 deubiquitinase activity, thus establishing a foundation for small-molecule approaches to reactivate latent wild-type BAP1 catalytic activity in BAP1-mutant cancers. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33731362      PMCID: PMC8254751          DOI: 10.1158/1541-7786.MCR-20-0080

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  30 in total

1.  Reconstitution of the KRAB-KAP-1 repressor complex: a model system for defining the molecular anatomy of RING-B box-coiled-coil domain-mediated protein-protein interactions.

Authors:  H Peng; G E Begg; D C Schultz; J R Friedman; D E Jensen; D W Speicher; F J Rauscher
Journal:  J Mol Biol       Date:  2000-02-04       Impact factor: 5.469

2.  De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome.

Authors:  Alexander Hoischen; Bregje W M van Bon; Benjamín Rodríguez-Santiago; Christian Gilissen; Lisenka E L M Vissers; Petra de Vries; Irene Janssen; Bart van Lier; Rob Hastings; Sarah F Smithson; Ruth Newbury-Ecob; Susanne Kjaergaard; Judith Goodship; Ruth McGowan; Deborah Bartholdi; Anita Rauch; Maarit Peippo; Jan M Cobben; Dagmar Wieczorek; Gabriele Gillessen-Kaesbach; Joris A Veltman; Han G Brunner; Bert B B A de Vries
Journal:  Nat Genet       Date:  2011-06-26       Impact factor: 38.330

Review 3.  Paradigms of protein degradation by the proteasome.

Authors:  Tomonao Inobe; Andreas Matouschek
Journal:  Curr Opin Struct Biol       Date:  2014-03-14       Impact factor: 6.809

4.  Identification of Novel Allosteric Modulators of Glutamate Transporter EAAT2.

Authors:  Sandhya Kortagere; Ole V Mortensen; Jingsheng Xia; William Lester; Yuhong Fang; Yellamelli Srikanth; Joseph M Salvino; Andréia C K Fontana
Journal:  ACS Chem Neurosci       Date:  2017-11-30       Impact factor: 4.418

5.  Structural Basis for the Activation of the Deubiquitinase Calypso by the Polycomb Protein ASX.

Authors:  Inessa De; Emily C Chittock; Helga Grötsch; Thomas C R Miller; Andrew A McCarthy; Christoph W Müller
Journal:  Structure       Date:  2019-01-10       Impact factor: 5.006

6.  Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1.

Authors:  Shahram Misaghi; Søren Ottosen; Anita Izrael-Tomasevic; David Arnott; Mohamed Lamkanfi; James Lee; Jinfeng Liu; Karen O'Rourke; Vishva M Dixit; Angus C Wilson
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

7.  Germline BAP1 mutations predispose to malignant mesothelioma.

Authors:  Joseph R Testa; Mitchell Cheung; Jianming Pei; Jennifer E Below; Yinfei Tan; Eleonora Sementino; Nancy J Cox; A Umran Dogan; Harvey I Pass; Sandra Trusa; Mary Hesdorffer; Masaki Nasu; Amy Powers; Zeyana Rivera; Sabahattin Comertpay; Mika Tanji; Giovanni Gaudino; Haining Yang; Michele Carbone
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

8.  An evolutionarily conserved DNA architecture determines target specificity of the TWIST family bHLH transcription factors.

Authors:  Andrew T Chang; Yuanjie Liu; Kasirajan Ayyanathan; Chris Benner; Yike Jiang; Jeremy W Prokop; Helicia Paz; Dong Wang; Hai-Ri Li; Xiang-Dong Fu; Frank J Rauscher; Jing Yang
Journal:  Genes Dev       Date:  2015-03-11       Impact factor: 11.361

9.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

Authors:  Omar Abdel-Wahab; Mazhar Adli; Lindsay M LaFave; Jie Gao; Todd Hricik; Alan H Shih; Suveg Pandey; Jay P Patel; Young Rock Chung; Richard Koche; Fabiana Perna; Xinyang Zhao; Jordan E Taylor; Christopher Y Park; Martin Carroll; Ari Melnick; Stephen D Nimer; Jacob D Jaffe; Iannis Aifantis; Bradley E Bernstein; Ross L Levine
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

10.  A bidentate Polycomb Repressive-Deubiquitinase complex is required for efficient activity on nucleosomes.

Authors:  Martina Foglizzo; Adam J Middleton; Abigail E Burgess; Jennifer M Crowther; Renwick C J Dobson; James M Murphy; Catherine L Day; Peter D Mace
Journal:  Nat Commun       Date:  2018-09-26       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.